| Previous Close | 33.320 |
| Open | 33.380 |
| Bid | 33.230 x 9500 |
| Ask | 33.240 x 8000 |
| Day's Range | 33.170 - 33.480 |
| 52 Week Range | 29.830 - 37.390 |
| Volume | 7,520,550 |
| Avg. Volume | 20,314,514 |
| Market Cap | 198.55B |
| Beta | 1.07 |
| PE Ratio (TTM) | 28.01 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Dividend & Yield | 1.28 (3.82%) |
| Ex-Dividend Date | 2017-08-02 |
| 1y Target Est | N/A |
- Market Realist•3 hours ago
Why Pfizer’s Sutent Could Witness a Modest Decline in 2017
In 2016, Pfizer’s (PFE) Sutent reported revenues of ~$1.1 billion, which represented a ~2% decline on a YoY (year-over-year) basis.
- Market Realist•4 hours ago
How Pfizer’s Vaccine Franchise Is Positioned in 2017
In 2016, Pfizer’s (PFE) Prevnar 13 reported revenues of ~$5.7 billion, which reflected a ~8% decline on a YoY (year-over-year) basis.
- Market Realist•6 hours ago
Why Xeljanz Could Boost Pfizer’s Revenue Growth
In 2016, Pfizer’s (PFE) Xeljanz reported revenues of ~$927 million, which reflected a ~77% growth YoY (year-over-year).
